Nordea Investment Management AB Has $3.26 Million Stake in DexCom, Inc. $DXCM

Nordea Investment Management AB trimmed its holdings in DexCom, Inc. (NASDAQ:DXCM) by 51.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,683 shares of the medical device company’s stock after selling 39,733 shares during the period. Nordea Investment Management AB’s holdings in DexCom were worth $3,264,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in DXCM. Brighton Jones LLC raised its position in shares of DexCom by 257.7% in the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after buying an additional 11,946 shares in the last quarter. Kentucky Retirement Systems Insurance Trust Fund bought a new position in DexCom in the first quarter valued at approximately $775,000. Flagship Harbor Advisors LLC increased its stake in DexCom by 65.5% in the first quarter. Flagship Harbor Advisors LLC now owns 9,667 shares of the medical device company’s stock valued at $660,000 after acquiring an additional 3,825 shares during the last quarter. Oppenheimer & Co. Inc. increased its stake in DexCom by 4.8% in the first quarter. Oppenheimer & Co. Inc. now owns 21,225 shares of the medical device company’s stock valued at $1,449,000 after acquiring an additional 974 shares during the last quarter. Finally, Asset Management One Co. Ltd. increased its stake in DexCom by 4.1% in the first quarter. Asset Management One Co. Ltd. now owns 253,355 shares of the medical device company’s stock valued at $17,302,000 after acquiring an additional 9,980 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

DXCM has been the topic of a number of recent analyst reports. Morgan Stanley lifted their price objective on shares of DexCom from $82.00 to $89.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 15th. Mizuho lifted their price objective on shares of DexCom from $95.00 to $100.00 and gave the company an “outperform” rating in a research note on Wednesday, July 16th. UBS Group boosted their target price on shares of DexCom from $105.00 to $106.00 and gave the stock a “buy” rating in a research note on Thursday, July 31st. The Goldman Sachs Group decreased their target price on shares of DexCom from $104.00 to $89.00 and set a “buy” rating on the stock in a research note on Wednesday, October 1st. Finally, Argus initiated coverage on shares of DexCom in a research note on Thursday, August 21st. They set a “buy” rating and a $100.00 target price on the stock. Three analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and a consensus target price of $96.40.

DexCom Stock Performance

NASDAQ DXCM opened at $69.75 on Wednesday. The firm’s fifty day moving average price is $72.95 and its two-hundred day moving average price is $77.70. The stock has a market cap of $27.35 billion, a PE ratio of 48.44, a PEG ratio of 1.44 and a beta of 1.47. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $93.25. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping analysts’ consensus estimates of $0.45 by $0.03. The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. DexCom’s revenue was up 15.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. On average, equities analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 1,466 shares of DexCom stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $80.00, for a total transaction of $117,280.00. Following the transaction, the executive vice president owned 105,223 shares in the company, valued at approximately $8,417,840. The trade was a 1.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kyle Malady sold 667 shares of DexCom stock in a transaction on Friday, September 5th. The stock was sold at an average price of $80.86, for a total transaction of $53,933.62. Following the transaction, the director owned 22,667 shares in the company, valued at approximately $1,832,853.62. This trade represents a 2.86% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,849 shares of company stock worth $564,733 in the last three months. 0.32% of the stock is currently owned by company insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.